Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma
Status:
Withdrawn
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
This is a multi-centre phase I/II trial with an initial dose finding phase for
cyclophosphamide and lenalidomide combined with fixed dose pembrolizumab for patients with
relapsed or relapsed / refractory multiple myeloma (MM) that have had at least 1 prior line
of therapy